Intellia Grants 67,150 RSUs to 13 New Hires

Biopharmaceutical company awards inducement grants under Nasdaq listing rule

Apr. 3, 2026 at 8:05pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a carefully arranged composition of polished metal and glass laboratory equipment, such as test tubes, beakers, and pipettes, against a clean, monochromatic background. The objects are lit dramatically to symbolize the precision and innovation of Intellia's gene editing technology.Intellia's strategic investment in top scientific talent aims to drive continued advancements in gene editing technology.Cambridge Today

Intellia Therapeutics, a leading biopharmaceutical company focused on CRISPR gene editing, announced that it has awarded 67,150 time-based restricted stock units (RSUs) to 13 new employees as a material inducement to employment. The RSUs will vest one-third annually over three years, subject to continued service.

Why it matters

The grants are part of Intellia's efforts to attract and retain top talent in the competitive biopharmaceutical industry, which is critical for the company's continued growth and development of potentially curative CRISPR-based treatments.

The details

The inducement grants were awarded on April 1, 2026 under Intellia's 2024 Inducement Plan, which was adopted by the company's board of directors to allow for the issuance of equity awards to new employees as a material inducement to joining the company. The grants were approved by Intellia's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).

  • The inducement grants were awarded on April 1, 2026.
  • The RSUs will vest one-third annually over three years.

The players

Intellia Therapeutics, Inc.

A leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies.

Jason Fredette

Vice President, Investor Relations and Corporate Communications at Intellia Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies.”

— Intellia Therapeutics

The takeaway

Intellia's inducement grants demonstrate the company's commitment to building a talented team to advance its CRISPR-based therapies, which could have a significant impact on the lives of people with severe diseases.